IHS Chemical Week

People & Business :: Earnings/Finance

Schulman, Ferro prepare for next stage in bid, proxy fight

2:15 PM MDT | April 15, 2013 | —Vincent Valk and Rebecca Coons

Ferro sold its pharmaceuticals business, increased its earnings guidance, and issued a letter to shareholders, while A. Schulman fell short of estimates and amended CEO Joseph Gingo’s contract to extend it in the event of a “transformational acquisition” as the companies hunkered down for the next stage in Schulman’s $855-million hostile bid for Ferro. Gingo’s revised contract provides for a two-year extension, and Schulman specifically mentioned Ferro as the kind of deal that could trigger the extension....

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa